ZhenGe Biotech Completes $51 Million A Round for CDMO Operations
publication date: Apr 1, 2020
Shanghai ZhenGe Biotech, a China CDMO, completed a $51 million Series A financing round led by Shanghai-based healthcare investment firm Lyfe Capital. The company will use the proceeds for additional hires and to expand its Shanghai R&D center, build a GMP production base in the Shanghai Pilot Free Trade Zone (a production facility for macromolecular drugs, growth media and ADC drugs), and expand its US lab. Also participating in the A round were IDG Capital, Cowin Capital, Korea Investment Partners, GT Capital and Shanghai International Group. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.